Logo

XLO

Xilio Therapeutics, Inc.

XLO

Xilio Therapeutics, Inc. • NASDAQ
$0.76 ▲ 1.00% (+0.01)
Market Cap $39.77 M
52w High $1.70
52w Low $0.61
Dividend Yield 0%
P/E -1.24
Volume 108.03K
Outstanding Shares 52.50M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $19.066M ▲ $20.655M ▲ $-16.287M ▼ -85.424% ▲ $-0.11 ▲ $-15.947M ▼
Q2-2025 $8.084M ▲ $7.12M ▼ $-15.844M ▼ -195.992% ▲ $-0.16 ▲ $-13.985M ▼
Q1-2025 $2.93M ▲ $16.781M ▲ $-13.265M ▼ -452.73% ▲ $-0.18 ▲ $-13.354M ▼
Q4-2024 $1.724M ▼ $15.353M ▼ $-13.093M ▲ -759.455% ▼ $-0.2 ▲ $-13.254M ▲
Q3-2024 $2.263M $17.025M $-14.02M -619.532% $-0.22 $-14.422M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $103.764M ▼ $133.694M ▼ $141.789M ▲ $-8.095M ▼
Q2-2025 $121.551M ▲ $133.813M ▲ $126.744M ▲ $7.069M ▼
Q1-2025 $89.073M ▲ $103.716M ▲ $93.016M ▲ $10.7M ▼
Q4-2024 $55.291M ▼ $71.075M ▼ $53.477M ▼ $17.598M ▼
Q3-2024 $61.259M $74.658M $53.684M $20.974M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-16.287M ▼ $-17.495M ▼ $0 ▲ $-285K ▼ $-17.787M ▼ $-17.495M ▼
Q2-2025 $-15.844M ▼ $-14.477M ▼ $-401K ▼ $47.362M ▲ $32.484M ▼ $-14.878M ▼
Q1-2025 $-13.265M ▼ $28.978M ▲ $-22K ▼ $4.832M ▼ $33.788M ▲ $28.956M ▲
Q4-2024 $-13.093M ▲ $-14.157M ▼ $-6K ▲ $8.202M ▲ $-5.961M ▲ $-14.163M ▼
Q3-2024 $-14.02M $-13.672M $-9K $-3K $-13.684M $-13.681M

Five-Year Company Overview

Income Statement

Income Statement Xilio is still very much a research-focused company, not a commercial one. It has essentially no product revenue yet, so the income statement is dominated by research and development and other operating costs. These expenses have led to steady losses each year, which is normal for an early-stage biotech. The size of the losses has started to ease a bit more recently, but the business is still firmly in the “spending to develop the pipeline” phase, with no operating profitability in sight until and unless a drug reaches market or substantial deal payments arrive.

Balance Sheet

Balance Sheet The balance sheet is lean and centered on cash and short-term assets, which is typical for a clinical-stage biotech. Cash levels were much higher a few years ago and have come down as the company has funded its trials, though there are signs of some stabilization more recently. Debt is very modest, so financial leverage risk appears limited. Shareholders’ equity turned from negative to positive and then has been gradually eroding as losses accumulate. Overall, the company still has a cash cushion but not a deep one, and its financial strength over time will depend heavily on its ability to raise additional capital or secure more partnership funding.

Cash Flow

Cash Flow Cash flow reflects a pure cash-burning R&D story. Operating cash flow has been consistently negative as the company spends on clinical trials, personnel, and overhead, with only a slight improvement in the most recent period. Capital spending is minimal, so almost all cash usage is tied directly to running the business and advancing the pipeline, not to big physical assets. This means future funding needs are likely to continue unless there is a major partnership or the company trims development pace. The path forward relies on access to capital markets or milestone payments rather than internally generated cash.

Competitive Edge

Competitive Edge Xilio’s competitive position rests on a specialized niche within cancer immunotherapy: tumor-selective, “masked” drugs designed to be safer and more effective. This is a crowded and fast-moving field, but the company’s focus on localized activation in tumors, rather than throughout the body, offers a clear conceptual differentiation. Partnerships with large pharma players signal external validation and give Xilio more credibility against bigger, better-funded rivals. Still, as a small clinical-stage biotech, it faces the usual disadvantages of limited scale, dependence on a few key programs, and exposure to setbacks if trial results disappoint or competing technologies move faster.

Innovation and R&D

Innovation and R&D Innovation is the core of Xilio’s identity and spending. The company is building a platform around masked immunotherapies—antibodies, cytokines, and T cell engagers—that are designed to switch on only inside tumors. Lead programs include a tumor-activated CTLA-4 antibody and an IL-12 therapy, both in human trials, plus earlier-stage masked T cell engagers aimed at well-known cancer targets. Collaborations with major drug makers around these assets and the platform show that the science is attracting interest. However, most of the value is still “on paper”: the programs are in relatively early or mid-stage development, so technical, clinical, and regulatory risks remain very high.

Summary

Xilio is a classic high-risk, high-potential biotech: minimal revenue, ongoing losses, and a business model that depends on turning promising science into successful clinical outcomes and strategic deals. Financially, the company is burning cash at a measured but steady pace, supported by a modest, largely debt-free balance sheet. Its long-term prospects are tied to the strength of its tumor-selective platform, the success of key clinical trials, and its ability to keep attracting partners and capital. The story is fundamentally about whether its innovative masking approach can translate into safer, more effective cancer therapies before financial resources become too tight. Uncertainty is high, but so is the potential impact if the pipeline delivers.

NEWS

November 13, 2025 · 7:30 AM UTC

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

Read more

November 7, 2025 · 9:05 AM UTC

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Read more

November 7, 2025 · 9:01 AM UTC

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Read more

November 3, 2025 · 4:30 PM UTC

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more

October 30, 2025 · 9:01 AM UTC

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

Read more